1 Huang L, "Virus infections incite pain hypersensitivity by inducing indoleamine 2, 3 dioxygenase" 12 : e1005615-, 2016
2 Laumet G, "Upregulation of neuronal kynurenine 3-monooxygenase mediates depression-like behavior in a mouse model of neuropathic pain" 66 : 94-102, 2017
3 Badawy AA, "Tryptophan metabolism, disposition and utilization in pregnancy" 35 : e00261-, 2015
4 Comai S, "Tryptophan in health and disease" 95 : 165-218, 2020
5 Savitz JB, "Treatment of bipolar depression with minocycline and/or aspirin : an adaptive, 2×2 double-blind, randomized, placebo-controlled, phase IIA clinical trial" 8 : 27-, 2018
6 Santana-Martínez RA, "The therapeutic effect of curcumin in quinolinic acid-induced neurotoxicity in rats is associated with BDNF, ERK1/2, Nrf2, and antioxidant enzymes" 8 : 388-, 2019
7 Rossi F, "The synthesis of kynurenic acid in mammals : an updated kynurenine aminotransferase structural katalogue" 6 : 7-, 2019
8 Duan KM, "The role of tryptophan metabolism in postpartum depression" 33 : 647-660, 2018
9 Quan C, "The role of kynurenine pathway and kynurenic aminotransferase alleles in postpartum depression following cesarean section in Chinese women" 10 : e01566-, 2020
10 Sayson LV, "The novel methoxetamine analogs N-ethylnorketamine hydrochloride(NENK), 2-MeO-N-ethylketamine hydrochloride(2-MeO-NEK), and 4-MeO-N-ethylketamine hydrochloride(4-MeO-NEK)elicit rapid antidepressant effects via activation of AMPA and 5-HT2 receptors" 236 : 2201-2210, 2019
11 Mándi Y, "The kynurenine system and immunoregulation" 119 : 197-209, 2012
12 Worton SA, "The kynurenine pathway; a new target for treating maternal features of preeclampsia" 84 : 44-49, 2019
13 Favennec M, "The kynurenine pathway is activated in human obesity and shifted toward kynurenine monooxygenase activation" 23 : 2066-2074, 2015
14 Erhardt S, "The kynurenine pathway in schizophrenia and bipolar disorder" 112 (112): 297-306, 2017
15 Schwarcz R, "The kynurenine pathway and the brain : challenges, controversies and promises" 112 (112): 237-247, 2017
16 Savitz J, "The kynurenine pathway : a finger in every pie" 25 : 131-147, 2020
17 Flis M, "The kynurenic acid hypothesis - a new look at etiopathogenesis and treatment of schizophrenia" 41 : 160-164, 2016
18 Guloksuz S, "The impact of electroconvulsive therapy on the tryptophan-kynurenine metabolic pathway" 48 : 48-52, 2015
19 Badawy AA, "The end of the road for the tryptophan depletion concept in pregnancy and infection" 130 : 1327-1333, 2016
20 Suzuki H, "Suicide and microglia : recent findings and future perspectives based on human studies" 13 : 31-, 2019
21 Meier TB, "Smaller dentate gyrus and CA2 and CA3 volumes are associated with kynurenine metabolites in collegiate football athletes" 33 : 1349-1357, 2016
22 Agudelo LZ, "Skeletal muscle PGC-1α1 modulates kynurenine metabolism and mediates resilience to stress-induced depression" 159 : 33-45, 2014
23 Steiner J, "Severe depression is associated with increased microglial quinolinic acid in subregions of the anterior cingulate gyrus: evidence for an immune-modulated glutamatergic neurotransmission?" 8 : 94-, 2011
24 Sakurai M, "Serum metabolic profiles of the tryptophan-kynurenine pathway in the high risk subjects of major depressive disorder" 10 : 1961-, 2020
25 Chiappelli J, "Salivary kynurenic acid response to psychological stress : inverse relationship to cortical glutamate in schizophrenia" 43 : 1706-1711, 2018
26 Dantzer R, "Role of the kynurenine metabolism pathway in inflammation-induced depression : preclinical approaches" 31 : 117-138, 2017
27 Brundin L, "Role of inflammation in suicide : from mechanisms to treatment" 42 : 271-283, 2017
28 Borsini A, "Rescue of IL-1-induced reduction of human neurogenesis by omega-3 fatty acids and antidepressants" 65 : 230-238, 2017
29 Leday GGR, "Replicable and coupled changes in innate and adaptive immune gene expression in two case-control studies of blood microarrays in major depressive disorder" 83 : 70-80, 2018
30 Kozak R, "Reduction of brain kynurenic acid improves cognitive function" 34 : 10592-10602, 2014
31 Gos T, "Reduced microglial immunoreactivity for endogenous NMDA receptor agonist quinolinic acid in the hippocampus of schizophrenia patients" 41 : 59-64, 2014
32 Lovelace MD, "Recent evidence for an expanded role of the kynurenine pathway of tryptophan metabolism in neurological diseases" 112 (112): 373-388, 2017
33 Guillemin GJ, "Quinolinic acid, the inescapable neurotoxin" 279 : 1356-1365, 2012
34 Baranyi A, "Quinolinic acid responses during interferon--induced depressive symptomatology in patients with chronic hepatitis c infection-a novel aspect for depression and inflammatory hypothesis" 10 : e0137022-, 2015
35 da Silveira TL, "Quinolinic acid and glutamatergic neurodegeneration in caenorhabditis elegans" 67 : 94-101, 2018
36 Savitz J, "Putative neuroprotective and neurotoxic kynurenine pathway metabolites are associated with hippocampal and amygdalar volumes in subjects with major depressive disorder" 40 : 463-471, 2015
37 Flores-Barrera E, "Preferential disruption of prefrontal GABAergic function by nanomolar concentrations of the α7nACh negative modulator kynurenic acid" 37 : 7921-7929, 2017
38 Al-Hakeim HK, "Plasma indoleamine-2, 3-dioxygenase(IDO)is increased in drugnaïve major depressed patients and treatment with sertraline and ketoprofen normalizes IDO in association with pro-inflammatory and immune-regulatory cytokines" 19 : 44-54, 2020
39 Pedersen BK, "Physical activity and muscle-brain crosstalk" 15 : 383-392, 2019
40 Weyh C, "Physical activity and diet shape the immune system during aging" 12 : 622-, 2020
41 Dounay AB, "PF-04859989 as a template for structure-based drug design : identification of new pyrazole series of irreversible KAT II inhibitors with improved lipophilic efficiency" 23 : 1961-1966, 2013
42 Majewski M, "Overview of the role of vitamins and minerals on the kynurenine pathway in health and disease" 67 : 3-19, 2016
43 Bortz DM, "Oral administration of a specific kynurenic acid synthesis(KAT II)inhibitor attenuates evoked glutamate release in rat prefrontal cortex" 121 : 69-78, 2017
44 Roman M, "Novel neuroimmunologic therapeutics in depression : a clinical perspective on what we know so far" 83 : 7-21, 2020
45 Parrott JM, "Neurotoxic kynurenine metabolism is increased in the dorsal hippocampus and drives distinct depressive behaviors during inflammation" 6 : e918-, 2016
46 Savitz J, "Neuroprotective kynurenine metabolite indices are abnormally reduced and positively associated with hippocampal and amygdalar volume in bipolar disorder" 52 : 200-211, 2015
47 Benedetti F, "Neuroinflammation in bipolar depression" 11 : 71-, 2020
48 Kim YK, "Neuroinflammation and the immune-kynurenine pathway in anxiety disorders" 16 : 574-582, 2018
49 Buckley PF, "Neuroinflammation and schizophrenia" 21 : 72-, 2019
50 Romain Troubat, "Neuroinflammation and depression: A review" Wiley 53 (53): 151-171, 2021
51 Myint AM, "Network beyond IDO in psychiatric disorders : revisiting neurodegeneration hypothesis" 48 : 304-313, 2014
52 Walker AK, "NMDA receptor blockade by ketamine abrogates lipopolysaccharide-induced depressive-like behavior in C57BL/6J mice" 38 : 1609-1616, 2013
53 Sas K, "Mitochondria, oxidative stress and the kynurenine system, with a focus on ageing and neuroprotection" 23 : 191-, 2018
54 Li H, "Microglial markers in the frontal cortex are related to cognitive dysfunctions in major depressive disorder" 241 : 305-310, 2018
55 Laskaris LE, "Microglial activation and progressive brain changes in schizophrenia" 173 : 666-680, 2016
56 Jacobs KR, "Major developments in the design of inhibitors along the kynurenine pathway" 24 : 2471-2495, 2017
57 Huang M, "Longitudinal association of inflammation with depressive symptoms : a 7-year cross-lagged twin difference study" 75 : 200-207, 2019
58 Fujigaki H, "Linking phencyclidine intoxication to the tryptophan-kynurenine pathway : therapeutic implications for schizophrenia" 125 : 1-6, 2019
59 Walker AK, "Leucine competes with kynurenine for blood-to-brain transport and prevents lipopolysaccharide-induced depression-like behavior in mice" 24 : 1523-1532, 2019
60 Cervenka I, "Kynurenines: tryptophan’s metabolites in exercise, inflammation, and mental health" 357 : eaaf9794-, 2017
61 Castro-Portuguez R, "Kynurenine pathway, NAD+synthesis, and mitochondrial function : targeting tryptophan metabolism to promote longevity and healthspan" 132 : 110841-, 2020
62 Young KD, "Kynurenine pathway metabolites are associated with hippocampal activity during autobiographical memory recall in patients with depression" 56 : 335-342, 2016
63 Bryleva EY, "Kynurenine pathway metabolites and suicidality" 112 (112): 324-330, 2017
64 Allen AP, "Kynurenine pathway metabolism and the neurobiology of treatment-resistant depression : comparison of multiple ketamine infusions and electroconvulsive therapy" 100 : 24-32, 2018
65 Braidy N, "Kynurenine pathway metabolism and neuroinflammatory disease" 12 : 39-42, 2017
66 Garrison AM, "Kynurenine pathway metabolic balance influences microglia activity : targeting kynurenine monooxygenase to dampen neuroinflammation" 94 : 1-10, 2018
67 Konstantinou G, "Kynurenine pathway in bipolar disorder" 29 : 338-348, 2018
68 Wu Y, "Kynurenine pathway changes in late-life depression" 235 : 76-81, 2018
69 Parrott JM, "Kynurenine metabolic balance is disrupted in the hippocampus following peripheral lipopolysaccharide challenge" 13 : 124-, 2016
70 Albuquerque EX, "Kynurenic acid as an antagonist of α7 nicotinic acetylcholine receptors in the brain: facts and challenges" 85 : 1027-1032, 2013
71 Lim CK, "Involvement of the kynurenine pathway in the pathogenesis of Parkinson’s disease" 155 : 76-95, 2017
72 Adams S, "Involvement of the kynurenine pathway in human glioma pathophysiology" 9 : e112945-, 2014
73 Lawson MA, "Intracerebroventricular administration of lipopolysaccharide induces indoleamine-2, 3-dioxygenasedependent depression-like behaviors" 10 : 87-, 2013
74 Jacobs KR, "Inhibiting the kynurenine pathway in spinal cord injury: multiple therapeutic potentials?" 13 : 2073-2076, 2018
75 Zakrocka I, "Influence of cyclooxygenase-2 inhibitors on kynurenic acid production in rat brain in vitro" 35 : 244-254, 2019
76 Achtyes E, "Inflammation and kynurenine pathway dysregulation in post-partum women with severe and suicidal depression" 83 : 239-247, 2020
77 Connor TJ, "Induction of indolamine 2,3-dioxygenase and kynurenine 3-monooxygenase in rat brain following a systemic inflammatory challenge: a role for IFN-gamma?" 441 : 29-34, 2008
78 Salazar A, "Indoleamine 2, 3-dioxygenase mediates anhedonia and anxiety-like behaviors caused by peripheral lipopolysaccharide immune challenge" 62 : 202-209, 2012
79 Zoga M, "Indoleamine 2, 3-dioxygenase and immune changes under antidepressive treatment in major depression in females" 28 : 633-638, 2014
80 Huang X, "Increased plasma kynurenic acid levels are associated with impaired attention/vigilance and social cognition in patients with schizophrenia" 16 : 263-271, 2020
81 Maes M, "Increased IgA and IgM responses against gut commensals in chronic depression : further evidence for increased bacterial translocation or leaky gut" 141 : 55-62, 2012
82 Tufvesson-Alm M, "Importance of kynurenine 3-monooxygenase for spontaneous firing and pharmacological responses of midbrain dopamine neurons : relevance for schizophrenia" 138 : 130-139, 2018
83 Wichers MC, "IDO and interferon-alpha-induced depressive symptoms : a shift in hypothesis from tryptophan depletion to neurotoxicity" 10 : 538-544, 2005
84 Qin Y, "IDO and TDO as a potential therapeutic target in different types of depression" 33 : 1787-1800, 2018
85 Agus A, "Gut microbiota regulation of tryptophan metabolism in health and disease" 23 : 716-724, 2018
86 Laurans L, "Genetic deficiency of indoleamine 2, 3-dioxygenase promotes gut microbiota-mediated metabolic health" 24 : 1113-1120, 2018
87 Alper Evrensel, "Fecal Microbiota Transplantation and Its Usage in Neuropsychiatric Disorders" 대한정신약물학회 14 (14): 231-237, 2016
88 Fallarini S, "Expression of functional GPR35 in human iNKT cells" 398 : 420-425, 2010
89 Schlittler M, "Endurance exercise increases skeletal muscle kynurenine aminotransferases and plasma kynurenic acid in humans" 310 : C836-C840, 2016
90 Kehr J, "Effects of cariprazine on extracellular levels of glutamate, GABA, dopamine, noradrenaline and serotonin in the medial prefrontal cortex in the rat phencyclidine model of schizophrenia studied by microdialysis and simultaneous recordings of locomotor activity" 235 : 1593-1607, 2018
91 Benatti C, "Disease-induced neuroinflammation and depression" 15 : 414-433, 2016
92 Kanchanatawan B, "Deficit, but not nondeficit, schizophrenia is characterized by mucosa-associated activation of the tryptophan catabolite(TRYCAT)pathway with highly specific increases in IgA responses directed to picolinic, xanthurenic, and quinolinic acid" 55 : 1524-1536, 2018
93 Baïlara KM, "Decreased brain tryptophan availability as a partial determinant of post-partum blues" 31 : 407-413, 2006
94 Pierozan P, "Cytoskeleton as a target of quinolinic acid neurotoxicity : insight from animal models" 55 : 4362-4372, 2018
95 Zhou Y, "Crosssectional relationship between kynurenine pathway metabolites and cognitive function in major depressive disorder" 101 : 72-79, 2019
96 Listunova L, "Cognitive impairment along the course of depression : non-pharmacological treatment options" 51 : 295-305, 2018
97 Kim BJ, "Clinical insights into the kynurenine pathway in age-related diseases" 130 : 110793-, 2020
98 Wu W, "Circulating T lymphocyte subsets, cytokines, and immune checkpoint inhibitors in patients with bipolar II or major depression : a preliminary study" 7 : 40530-, 2017
99 Martín-Hernández D, "Chronic mild stress alters kynurenine pathways changing the glutamate neurotransmission in frontal cortex of rats" 56 : 490-501, 2019
100 Dounay AB, "Challenges and opportunities in the discovery of new therapeutics targeting the kynurenine pathway" 58 : 8762-8782, 2015
101 Raison CL, "CSF concentrations of brain tryptophan and kynurenines during immune stimulation with IFN-alpha : relationship to CNS immune responses and depression" 15 : 393-403, 2010
102 Kim H, "Brain indoleamine 2, 3-dioxygenase contributes to the comorbidity of pain and depression" 122 : 2940-2954, 2012
103 Małyszczak K, "Biological and psychological components of depression in patients receiving IFN-alpha therapy for hepatitis C" 28 : 1217-1222, 2019
104 Price JB, "Bioenergetics and synaptic plasticity as potential targets for individualizing treatment for depression" 90 : 212-220, 2018
105 Baranyi A, "Beta-trace protein as a new non-invasive immunological marker for quinolinic acid-induced impaired blood-brain barrier integrity" 7 : 43642-, 2017
106 Vallerand IA, "Assessment of a bidirectional association between major depressive disorder and alopecia areata" 155 : 475-479, 2019
107 Zhou Y, "Antidepressant effect of repeated ketamine administration on kynurenine pathway metabolites in patients with unipolar and bipolar depression" 74 : 205-212, 2018
108 Brundin L, "An enzyme in the kynurenine pathway that governs vulnerability to suicidal behavior by regulating excitotoxicity and neuroinflammation" 6 : e865-, 2016
109 Zádori D, "Alzheimer’s disease : recent concepts on the relation of mitochondrial disturbances, excitotoxicity, neuroinflammation, and kynurenines" 62 : 523-547, 2018
110 Johansson AS, "Activation of kynurenine pathway in ex vivo fibroblasts from patients with bipolar disorder or schizophrenia : cytokine challenge increases production of 3-hydroxykynurenine" 47 : 1815-1823, 2013
111 Serafini G, "Abnormalities in kynurenine pathway metabolism in treatment-resistant depression and suicidality : a systematic review" 16 : 440-453, 2017
112 Song P, "Abnormal kynurenine pathway of tryptophan catabolism in cardiovascular diseases" 74 : 2899-2916, 2017
113 Bay-Richter C, "A role for inflammatory metabolites as modulators of the glutamate N-methyl-D-aspartate receptor in depression and suicidality" 43 : 110-117, 2015
114 Park LT, "A randomized trial of the N-Methyl-d-aspartate receptor glycine site antagonist prodrug 4-chlorokynurenine in treatment-resistant depression" 23 : 417-425, 2020
115 Condray R, "3-Hydroxykynurenine and clinical symptoms in first-episode neuroleptic-naive patients with schizophrenia" 14 : 756-767, 2011